SCHEMBL30165286

SCHEMBL30165286

C=CC(=O)N[C@H]1C[C@@H](C(=O)Nc2ccc(NC(=O)c3cccc(-c4ccn[nH]4)n3)nc2)CN(CC(F)(F)F)C1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IRAK1 P51617 7/20 0.47
MAP3K19 Q56UN5 1/20 0.45
IRAK4 Q9NWZ3 3/20 0.39
NPC1 O15118 5/20 0.38
RAB9A P51151 5/20 0.38
TP53 P04637 3/20 0.38
ALDH1A1 P00352 2/20 0.38
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
ABL1 P00519 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
PTBP1 P26599 1/20 0.34
ACKR3 P25106 1/20 0.33
CDK14 O94921 1/20 0.33
CCNY Q8ND76 1/20 0.33
BCR P11274 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23860699 1.00 IRAK1 (0.47) IRAK1MAP3K19IRAK4NPC1RAB9A
SCHEMBL30165287 0.91 IRAK1 (0.48) IRAK1MAP3K19IRAK4NPC1RAB9A
SCHEMBL23860732 0.91 IRAK1 (0.48) IRAK1MAP3K19IRAK4NPC1RAB9A
SCHEMBL30279677 0.88 IRAK1 (0.51) IRAK1MAP3K19IRAK4NPC1RAB9A
SCHEMBL27084620 0.88 IRAK1 (0.51) IRAK1MAP3K19IRAK4NPC1RAB9A
SCHEMBL30165301 0.86 NPC1 (0.38) NPC1RAB9ATP53ALDH1A1PKM
SCHEMBL23860734 0.86 NPC1 (0.38) NPC1RAB9ATP53ALDH1A1PKM
SCHEMBL23860746 0.84 IRAK1 (0.53) IRAK1MAP3K19IRAK4NPC1RAB9A
SCHEMBL23860709 0.84 IRAK1 (0.53) IRAK1MAP3K19IRAK4NPC1RAB9A
SCHEMBL30165339 0.84 IRAK1 (0.53) IRAK1MAP3K19IRAK4NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4125895-A1 POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 Dana-Farber Cancer Institute, Inc. (US) 2023-02-08 EP disclosed